Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology

Table 1 Clinical and biochemical characteristics of samples in the first part of the study n (%)

	Training set				Blind test set				P-value1
	Malignant	Benign	Healthy	P-value	Malignant	Benign	Healthy	P-value
Sex
Male	13 (56.52)	10 (55.56)	12 (60.00)	0.957	10 (45.45)	5 (50.00)	5 (33.33)	0.662	0.665
Female	10 (43.48)	8 (44.44)	8 (40.00)		12 (54.55)	5 (50.00)	10 (66.67)
Age (yr, mean ± SD)	62.61 ± 12.71	60.61 ± 8.51	55.50 ± 13.13	0.145	65.14 ± 13.02	59.10 ± 14.15	63.07 ± 12.60	0.402	0.18
Pathology
Ductal adenocarcinoma	23 (100.00)				22 (100.00)
Mucinous cystadenoma		7 (38.89)				2 (20.00)
Solid pseudopapillary tumor		4 (22.22)
Insulinoma		3 (16.67)				3 (30.00)
Serous cystadenoma		2 (11.11)				3 (30.00)
Intraductal papillary mucinous tumor		2 (11.11)				2 (20.00)
CA19-9 (U/mL, mean ± SD)	10.66 ± 8.92	11.94 ± 6.93	9.67 ± 6.94	0.382	12.45 ± 9.69	15.51 ± 11.60	10.00 ± 8.27	0.557	0.667

¹P value between the two sets. CA: Carbohydrate antigen.